HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures-Reference-Cited by-同舟云学术

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

Published:2017-03-13 Issue:4 Volume:23 Page:517-525
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Davies Helen,Glodzik Dominik,Morganella Sandro,Yates Lucy R,Staaf Johan,Zou Xueqing,Ramakrishna Manasa,Martin Sancha,Boyault Sandrine,Sieuwerts Anieta M^ORCID,Simpson Peter T,King Tari A,Raine Keiran^ORCID,Eyfjord Jorunn E,Kong Gu,Borg Åke,Birney Ewan,Stunnenberg Hendrik G,van de Vijver Marc J,Børresen-Dale Anne-Lise,Martens John W M^ORCID,Span Paul N,Lakhani Sunil R,Vincent-Salomon Anne,Sotiriou Christos,Tutt Andrew^ORCID,Thompson Alastair M,Van Laere Steven,Richardson Andrea L,Viari Alain,Campbell Peter J,Stratton Michael R,Nik-Zainal Serena

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4292.pdf

Reference51 articles.

1. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 83, 1301–1308 (2000).

2. John, E.M. et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. J. Am. Med. Assoc. 298, 2869–2876 (2007).

3. Malone, K.E. et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 66, 8297–8308 (2006).

4. Couch, F.J., Nathanson, K.L. & Offit, K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343, 1466–1470 (2014).

5. King, M.C. “The race” to clone BRCA1. Science 343, 1462–1465 (2014).

Cited by 802 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on trends in development and translation of omics signatures in cancer;Computational and Structural Biotechnology Journal;2024-12

2. Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells;Scientific Reports;2024-09-13

3. A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer;The Prostate;2024-09-09

4. A 15-Gene prognostic signature with TFAP2B functioning in Platinum Resistance of Ovarian Carcinoma;2024-09-09

5. Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility;Nature Communications;2024-09-04